Bio-Techne Corp
TECH: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$61.00 | Ysswbby | Srrfdjld |
Bio-Techne Gets a Top-Line Boost From High-Growth ExoDx; Flat Q1 Margin Meets Expectations
Bio-Techne had a good quarter overall and remains on track to exceed $1 billion of sales this year. We are leaving our $320 fair value estimate and narrow moat ratings in place as quarterly results did not deviate much from our perspective. Shares remain slightly overvalued, in our view.